PharmaEssentia Corporation (TPE:6446)
Taiwan · Delayed Price · Currency is TWD 689.00
+19.00 (2.84%)
At close: Mar 5, 2026
PharmaEssentia Revenue
In the year 2025, PharmaEssentia had annual revenue of 15.63B TWD with 60.61% growth. PharmaEssentia had revenue of 4.88B in the quarter ending December 31, 2025, with 59.44% growth.
Revenue
15.63B
Revenue Growth
+60.61%
P/S Ratio
16.36
Revenue / Employee
119.35M
Employees
131
Market Cap
255.73B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15.63B | 5.90B | 60.61% |
| Dec 31, 2024 | 9.73B | 4.63B | 90.67% |
| Dec 31, 2023 | 5.11B | 2.22B | 77.15% |
| Dec 31, 2022 | 2.88B | 2.23B | 339.00% |
| Dec 31, 2021 | 656.51M | 99.25M | 17.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bora Pharmaceuticals | 21.10B |
| Lotus Pharmaceutical | 18.66B |
| Grape King Bio | 10.40B |
| YungShin Global Holding | 8.37B |
| TTY Biopharm Company | 6.50B |
| Synmosa Biopharma | 6.11B |
| ScinoPharm Taiwan | 3.19B |
| Handa Pharmaceuticals | 1.62B |
PharmaEssentia News
- 7 weeks ago - PharmaEssentia Says FDA Accepts SBLA For ET Treatment Ropeginterferon Alfa-2b-njft - Nasdaq
- 1 year ago - ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon alfa-2b) - Benzinga